InflaRx (IFRX) rose 5% Wednesday, after it said European regulators allowed the use of Gohibic monoclonal antibody to treat adult patients with SARS-CoV-2-induced acute respiratory distress syndrome in exceptional circumstances.
The approval allows the use of Gohibic for patients who are already receiving systemic corticosteroids and using mechanical ventilation as part of their Covid treatment for respiratory distress, the biotechnology company said.
It becomes the first therapy for COVID-19 approved for 27 European Union member states, along with Iceland, Liechtenstein and Norway.
InflaRx also said it is exploring potential commercial partnerships and distribution agreements to commercialize Gohibic in Europe. It does not expect the approach will negatively affect cash burn rate.
Price: 2.46, Change: +0.12, Percent Change: +5.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。